Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes
considerable morbidity and mortality.
Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2
infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination
with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients
with COVID-19.
Phase:
Phase 2
Details
Lead Sponsor:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau